SCHEMBL18317296

SCHEMBL18317296

CN(C(=O)C(Cc1cc(F)cc(F)c1)NC(=O)OC(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 8/20 0.46
CTSK P43235 7/20 0.46
CTSL P07711 2/20 0.44
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
ACE P12821 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
CACNA1B Q00975 1/20 0.40
CTSB P07858 2/20 0.40
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39
PTPN1 P18031 1/20 0.38
KLK5 Q9Y337 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18180261 1.00 CTSS (0.46) CTSSCTSKCTSLPPARGPPARA
SCHEMBL18180269 0.91 CTSS (0.47) CTSSCTSKCTSLACECTSB
SCHEMBL18180278 0.90 CTSS (0.47) CTSSCTSKCTSLACECTSB
SCHEMBL19962117 0.90 CTSS (0.46) CTSSCTSKCTSLACEALDH1A1
SCHEMBL19969242 0.89 CTSS (0.53) CTSSCTSKCTSLPPARGPPARA
SCHEMBL18179931 0.89 CTSS (0.53) CTSSCTSKCTSLPPARGPPARA
SCHEMBL18181379 0.89 CTSS (0.44) CTSSCTSKCTSLACEALDH1A1
SCHEMBL18180266 0.89 CTSS (0.44) CTSSCTSKCTSLACEALDH1A1
SCHEMBL18317994 0.89 CTSS (0.46) CTSSCTSKCTSLPPARGPPARA
SCHEMBL18181038 0.89 CTSS (0.46) CTSSCTSKCTSLACECTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286166-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2020-05-13 EP disclosed
US-10202353-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2019-02-12 US disclosed
US-20160368881-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368881-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, RPL35 CTSS 379/4885CTSK 780/4885CTSL 309/4885
US-10202353-B2 Therapeutic compounds RPL35, SARS1, HAVCR2 CTSS 436/4885CTSK 782/4885CTSL 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.